<a href="https://www.fiercebiotech.com/biotech/bms-calls-time-zymeworks-collab-ending-work-phase-1-stage-cancer-bispecific" hreflang="en">BMS calls time on Zymeworks collab, ending work on phase 1 cancer bispecific </a>
Bristol Myers Squibb has ended its collaboration with Zymeworks on a bispecific antibody targeting cancer, which was inherited from Celgene, and has removed the candidate from its phase 1 pipeline. The decision reflects BMS's strategy to prioritize resources on programs with higher potential impact for patients.
Bristol Myers Squibb has discontinued its collaboration with Zymeworks on a phase 1 bispecific antibody targeting CD40 and fibroblast activation protein, reflecting BMS's strategic shift in prioritizing programs with higher potential impact. This signals potential opportunities for Zymeworks to independently advance or re-partner this candidate, and highlights the importance for healthtech investors to monitor shifts in big pharma partnerships as indicators of strategic realignment and emerging opportunities in oncology drug development.